Treatment trends and risks of corticosteroid use in adult primary immune thrombocytopenia: a claims database study in Japan.

Autor: Kashiwagi H; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Postal Address: 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. kashi@hp-blood.med.osaka-u.ac.jp.; Osaka Red Cross Blood Center, Osaka, Japan. kashi@hp-blood.med.osaka-u.ac.jp., Miura I; Medical Department, Kissei Pharmaceutical Co., Ltd, Tokyo, Japan., Terasawa N; Medical Department, Kissei Pharmaceutical Co., Ltd, Tokyo, Japan., Iwayama KI; Medical Department, Kissei Pharmaceutical Co., Ltd, Tokyo, Japan., Furukawa Y; RWE Group Clinical Research Department, Ark Medical Solutions Inc, Tokyo, Japan., Kanenishi M; RWE Group Clinical Research Department, Ark Medical Solutions Inc, Tokyo, Japan.
Jazyk: angličtina
Zdroj: International journal of hematology [Int J Hematol] 2024 Dec 12. Date of Electronic Publication: 2024 Dec 12.
DOI: 10.1007/s12185-024-03897-8
Abstrakt: Recent trends in the treatment of primary immune thrombocytopenia (ITP) were investigated using a claims database that included data from 16,161 Japanese patients with ITP collected from April 2014 to August 2022. Of the 4144 adult patients analyzed, 1276 received corticosteroids. The mean and median durations of corticosteroid use were 115.31 and 41 days, respectively. The time to withdrawal of corticosteroids was significantly shorter in 2020 to 2021 than in 2015 to 2019. Additionally, the number of prescriptions for thrombopoietin receptor agonists increased from 2015 to 2021 and exceeded that of corticosteroids in 2021. While these results suggest a trend towards reduction in corticosteroid use in real-world settings in Japan, 12.00% of patients received a corticosteroid dose of ≥ 10 mg/day at Week 12. Furthermore, 23.05% of patients continued to receive corticosteroids at Week 24, indicating that some patients were still receiving long-term corticosteroid treatment. The risk of adverse outcomes was significantly associated with corticosteroid use. In conclusion, new treatment options may lead to more sophisticated ITP management with less corticosteroid use, although further research and reconsideration of clinical practice guidelines is needed.
Competing Interests: Declarations. Conflict of interest: HK is a member of the Editorial Board in International Journal of Hematology, and has received honoraria from Kissei Pharmaceutical Co., Ltd., argenx Japan, Novartis Pharma K.K and Sysmex Corporation. IM, NT and KI are employees of Kissei Pharmaceutical Co., Ltd. YF and MK are employees of Ark Medical Solutions Inc. Ethical approval: The study was approved by the Institutional Review Board of MINS, a specified nonprofit corporation and was conducted in accordance with the principles of the Declaration of Helsinki. This study protocol was registered in UMIN Clinical Trials Registry (Trial Number: UMIN000052806). Informed consent: The requirement for informed consent was waived because of the anonymity of patient data.
(© 2024. Japanese Society of Hematology.)
Databáze: MEDLINE
Externí odkaz: